The purpose of this study was to evaluate the efficacy of conventional diffusion weighted imaging (DWI), intravoxel incoherent motion (IVIM) imaging and diffusion kurtosis imaging (DKI) in assessing IDH1 mutation status and MGMT promoter methylation status in gliomas. In lower-grade gliomas, diffusion MRI parameters were able to significantly distinguish the mutation status of IDH1 and the methylation status of MGMT promoter, which is helpful for predicting prognosis and sensitivity to alkylating chemotherapeutic agents of patients. However, in glioblastomas, there was no significant difference between mutant and wild-type IDH1 as well as methylation and unmethylation status of the MGMT promoter.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords